Author

K. K. Saini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Verma· 4 shared D. Datta· 4 shared M. A. Nengroo· 4 shared A. Singh· 3 shared P. Chaturvedi· 3 shared A. K. Singh· 2 shared A. Sinha· 2 shared J. Sarkar· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Verma

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ACSL4 activity drives TNBC metastasis by positively regulating Histone H3 Acetylation mediated SNAIL expression

A. Sinha, K. K. Saini, K. Tripathi, M. A. Khan, S. R. Satrusal, A. Verma, B. Mandal, P. Rai, S. Meena, M. A. Nengroo, M. P. Singh, N. S. Bhushan, M. Vasudevan, A. Singhai, K. Singh, , D. Datta

This study identifies ACSL4 as a driver of TNBC metastasis by enhancing histone acetylation and SNAIL expression through metabolic and epigenetic mechanisms.

bioRxiv · Oct 16, 2023 · PreprintCancer Biology

PERK arm of UPR selectively regulates ferroptosis in colon cancer cells by modulating the expression of SLC7A11 (System Xc-)

K. K. Saini, P. Chaturvedi, A. Sinha, M. P. Singh, M. A. Khan, A. Verma, M. A. Nengroo, S. R. Satrusal, S. Meena, A. Singh, S. Srivastava, J. Sarkar, D. Datta

This study shows that PERK inhibition reduces SLC7A11 expression and sensitizes colon cancer cells to ferroptosis, suggesting PERK inhibitors as potential therapeutics.

bioRxiv · Mar 28, 2023 · PreprintCancer Biology

Salinomycin inhibits epigenetic modulator EZH2 to enhance Death Receptors in Colon Cancer Stem Cells

A. K. Singh, A. Verma, A. Singh, R. K. Arya, S. Maheshwari, P. Chaturvedi, M. A. Nengroo, K. K. Saini, A. L. Vishwakarma, K. Singh, J. Sarkar, D. Datta

This study shows salinomycin inhibits EZH2 in colon CSCs, enhancing DR4/DR5 expression and reducing CSC traits, suggesting a therapeutic strategy combining TRAIL and EZH2 inhibitors.

bioRxiv · Feb 3, 2020Cancer Biology

CXCR4 intracellular protein regulates drug resistance and tumorigenic potential via modulating the expression of Death Receptor 5

M. A. Nengroo, S. Maheshwari, A. Singh, A. K. Singh, R. K. Arya, P. Chaturvedi, A. Verma, K. K. Saini, A. Gupta, A. Mishra, D. Datta

The paper shows that intracellular CXCR4 protein, not its signaling, promotes drug resistance and tumorigenicity by downregulating DR5 through transcription factor modulation.

bioRxiv · Nov 15, 2019Cancer Biology